Anti-Human PCSK9 Reference Antibody (MEDI4166, RUO) (HV275166)

Name: Anti-Human PCSK9 Reference Antibody (MEDI4166, RUO)
Brand: abinScience
SKU: HV275166
Price: 370 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号	HV275166
説明	Anti-Human PCSK9 (MEDI4166) (HV275166) is a research-grade recombinant antibody targeting Proprotein convertase subtilisin/kexin type 9. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性	Human
アプリケーション	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
宿主種	Human
クローン性	Monoclonal
アイソタイプ	IgG
クローンID	MEDI4166
ターゲット	EC:3.4.21.-, NARC-1, NARC1, Neural apoptosis-regulated convertase 1, PC9, PCSK9, Proprotein convertase 9, Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9
エンドトキシンレベル	< 10 EU/mg
純度	>95% as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	Q8NBP7
形態	Liquid
保存バッファー	0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名	MEDI4166
背景	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha). 1. Poirier, S. et al. (2008) The Journal of biological chemistry 283, 2363-72. PMID: 18039658 2. Nassoury, N. et al. (2007) Traffic (Copenhagen, Denmark) 8, 718-32. PMID: 17461796 3. Fan, D. et al. (2008) Biochemistry 47, 1631-9. PMID: 18197702 4. Mayer, G. et al. (2008) The Journal of biological chemistry 283, 31791-801. PMID: 18799458 5. Chen, Y. et al. (2011) Biochemical and biophysical research communications 415, 515-8. PMID: 22074827 6. Jonas, MC. et al. (2008) EMBO reports 9, 916-22. PMID: 18660751
注意事項	For research use only. Not suitable for clinical or therapeutic use.